| Host: |
Rabbit |
| Applications: |
IF |
| Reactivity: |
Human/Mouse/Rat |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Rabbit polyclonal antibody anti-FAP (26-760) is suitable for use in Immunofluorescence research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
PBS with 0.01% Thimerosal, 50% Glycerol, pH7.3. |
| Purification: |
Affinity purification |
| Dilution Range: |
IF/ICC 1:50-1:200 |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
FAP |
| Gene ID: |
2191 |
| Uniprot ID: |
SEPR_HUMAN |
| Immunogen Region: |
26-760 |
| Immunogen: |
Recombinant fusion protein containing a sequence corresponding to amino acids 26-760 of human Fibroblast activation protein-Alpha (FAP) (NP_004451.2). |
| Immunogen Sequence: |
LRPSRVHNSEENTMRALTLK DILNGTFSYKTFFPNWISGQ EYLHQSADNNIVLYNIETGQ SYTILSNRTMKSVNASNYGL SPDRQFVYLESDYSKLWRYS YTATYYIYDLSNGEFVRGNE LPRPIQYLCWSPVGSKLAYV YQNNIYLKQRPGDPPFQITF NGRENKIFNGIPDWVYEEEM LATKYALWWSPNGKFLAYAE FNDTDIPVIAYSYYGDEQYP RTINIPYPKAGAKNPVVRI |
| Tissue Specificity | Expressed in adipose tissue. Expressed in the dermal fibroblasts in the fetal skin. Expressed in the granulation tissue of healing wounds and on reactive stromal fibroblast in epithelial cancers. Expressed in activated fibroblast-like synoviocytes from inflamed synovial tissues. Expressed in activated hepatic stellate cells (HSC) and myofibroblasts from cirrhotic liver, but not detected in normal liver. Expressed in glioma cells (at protein level). Expressed in glioblastomas and glioma cells. Isoform 1 and isoform 2 are expressed in melanoma, carcinoma and fibroblast cell lines. |
| Post Translational Modifications | N-glycosylated. The N-terminus may be blocked. |
| Function | Cell surface glycoprotein serine protease that participates in extracellular matrix degradation and involved in many cellular processes including tissue remodeling, fibrosis, wound healing, inflammation and tumor growth. Both plasma membrane and soluble forms exhibit post-proline cleaving endopeptidase activity, with a marked preference for Ala/Ser-Gly-Pro-Ser/Asn/Ala consensus sequences, on substrate such as alpha-2-antiplasmin SERPINF2 and SPRY2. Degrade also gelatin, heat-denatured type I collagen, but not native collagen type I and IV, vitronectin, tenascin, laminin, fibronectin, fibrin or casein. Also has dipeptidyl peptidase activity, exhibiting the ability to hydrolyze the prolyl bond two residues from the N-terminus of synthetic dipeptide substrates provided that the penultimate residue is proline, with a preference for Ala-Pro, Ile-Pro, Gly-Pro, Arg-Pro and Pro-Pro. Natural neuropeptide hormones for dipeptidyl peptidase are the neuropeptide Y (NPY), peptide YY (PYY), substance P (TAC1) and brain natriuretic peptide 32 (NPPB). The plasma membrane form, in association with either DPP4, PLAUR or integrins, is involved in the pericellular proteolysis of the extracellular matrix (ECM), and hence promotes cell adhesion, migration and invasion through the ECM. Plays a role in tissue remodeling during development and wound healing. Participates in the cell invasiveness towards the ECM in malignant melanoma cancers. Enhances tumor growth progression by increasing angiogenesis, collagen fiber degradation and apoptosis and by reducing antitumor response of the immune system. Promotes glioma cell invasion through the brain parenchyma by degrading the proteoglycan brevican. Acts as a tumor suppressor in melanocytic cells through regulation of cell proliferation and survival in a serine protease activity-independent manner. |
| Protein Name | Prolyl Endopeptidase Fap170 Kda Melanoma Membrane-Bound GelatinaseDipeptidyl Peptidase FapFibroblast Activation Protein AlphaFapalphaGelatine Degradation Protease FapIntegral Membrane Serine ProteasePost-Proline Cleaving EnzymeSerine Integral Membrane ProteaseSimpSurface-Expressed ProteaseSeprase Cleaved Into - Antiplasmin-Cleaving Enzyme Fap - Soluble FormApce |
| Cellular Localisation | Prolyl Endopeptidase Fap: Cell SurfaceCell MembraneSingle-Pass Type Ii Membrane ProteinCell ProjectionLamellipodium MembraneInvadopodium MembraneRuffle MembraneMembraneLocalized On Cell Surface With Lamellipodia And Invadopodia Membranes And On Shed VesiclesColocalized With Dpp4 At Invadopodia And Lamellipodia Membranes Of Migratory Activated Endothelial Cells In Collagenous MatrixColocalized With Dpp4 On Endothelial Cells Of Capillary-Like Microvessels But Not Large Vessels Within Invasive Breast Ductal CarcinomaAnchored And Enriched Preferentially By Integrin Alpha-3/Beta-1 At InvadopodiaPlasma Membrane Protrusions That Correspond To Sites Of Cell InvasionIn A Collagen-Dependent MannerLocalized At Plasma And Ruffle Membranes In A Collagen-Independent MannerColocalized With Plaur Preferentially At The Cell Surface Of Invadopodia Membranes In A Cytoskeleton-Integrin- And Vitronectin-Dependent MannerConcentrated At Invadopodia MembranesSpecialized Protrusions Of The Ventral Plasma Membrane In A Fibrobectin-Dependent MannerColocalizes With Extracellular Components (Ecm)Such As Collagen Fibers And FibronectinAntiplasmin-Cleaving Enzyme FapSoluble Form: SecretedFound In Blood Plasma And SerumIsoform 2: Cytoplasm |
| Alternative Antibody Names | Anti-Prolyl Endopeptidase Fap antibodyAnti-170 Kda Melanoma Membrane-Bound Gelatinase antibodyAnti-Dipeptidyl Peptidase Fap antibodyAnti-Fibroblast Activation Protein Alpha antibodyAnti-Fapalpha antibodyAnti-Gelatine Degradation Protease Fap antibodyAnti-Integral Membrane Serine Protease antibodyAnti-Post-Proline Cleaving Enzyme antibodyAnti-Serine Integral Membrane Protease antibodyAnti-Simp antibodyAnti-Surface-Expressed Protease antibodyAnti-Seprase Cleaved Into - Antiplasmin-Cleaving Enzyme Fap - Soluble Form antibodyAnti-Apce antibodyAnti-FAP antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
